stockportfolio.pro
Fulcrum Therapeutics, Inc. (FULC)
Healthcare · Biotechnology · NasdaqGM
Fulcrum Therapeutics, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $8.82M | $19.16M | $6.34M | $2.81M | $80.00M | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-32.59M | $-82.68M | $-70.82M | $-80.85M | $-109.87M | $-97.33M | $-9.72M | $-74.88M |
| Net margin | — | — | -802.7% | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
Source: Fulcrum Therapeutics, Inc. SEC filings (10-K).
Explore 8 years of Fulcrum Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track FULC in your portfolio →
Fulcrum Therapeutics, Inc. financial history by metric
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics, Inc. — frequently asked questions
What is Fulcrum Therapeutics, Inc.'s revenue?
Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Fulcrum Therapeutics, Inc. profitable?
No — FULC reported a net loss of $-74.88M in fiscal 2025.
What is FULC's P/E ratio?
Fulcrum Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Fulcrum Therapeutics, Inc. have?
As of fiscal year 2025, FULC carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Fulcrum Therapeutics, Inc.'s market cap?
Fulcrum Therapeutics, Inc. (FULC) has a market capitalization of about $232.22M, based on the latest data in our nightly-refreshed cache.
When does Fulcrum Therapeutics, Inc.'s fiscal year end?
FULC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Fulcrum Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.